Haemonetics Q1 FY27 adjusted EPS rises 4% to $1.14; revenue climbs 5.6% to $339.4 million - HAE News | RalliesHaemonetics Q1 FY27 adjusted EPS rises 4% to $1.14; revenue climbs 5.6% to $339.4 million
H
HAE• Q1 fiscal 2027 results
- Haemonetics posted Q1 fiscal 2027 GAAP net income of $33 million, down 2.94% year over year; GAAP EPS rose to $0.72 from $0.70.
- GAAP revenue climbed 5.6% to $339.4 million; Apheresis increased 5.3% to $191.3 million, and MedSurg rose 6% to $148.1 million.
- GAAP operating income rose 6.68% to $57.5 million, while the GAAP net income margin narrowed 0.9 percentage points to 9.7%.
- Non-GAAP adjusted EPS increased 3.64% to $1.14, while the non-GAAP adjusted operating margin slipped 0.7 percentage points to 23.4%.
- Full-year fiscal 2027 organic revenue growth outlook was raised to 4%-7%, while free cash flow conversion guidance stayed near 80%.
CRLBF
•
